The trajectory of copyright's flagship drug presents a interesting case for stakeholders in the pharmaceutical sector. While initially a phenomenal success, producing vast sums, the exclusivity lapse and the subsequent entry of off-brand alternatives have considerably changed income. This raises questions about the future viability of related thera